Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform

Credit Suisse initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Outperform rating and a price target of $44.00.

Analyst V. Divan commented, "We see AIMT as one of the leaders in developing treatments to help manage life-threatening food allergies, with an initial focus on the large unmet need in the peanut allergies. Its lead product, AR101, has shown encouraging efficacy and safety data in phase 2, with phase 3 scheduled to start in early 2016 and end in 2H 2017, setting the stage for potential commercial launch in 2018."

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $21.11 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'